Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: Results from the E-Five Registry

Heart

Volumn 96, Issue 11, 2010, Pages 848-853

  Jain, Ajay K ^a   Lotan, Chaim ^b   Meredith, Ian T ^c   Feres, Faustos ^d   Zambahari, Robaayah ^e   Sinha, Nakul ^f   Rothman, Martin T ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c MONASH UNIVERSITY   (Australia)

^d INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^e NATIONAL HEART INSTITUTE   (Malaysia)

^f SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; ASIA; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RETROSPECTIVE STUDY; REVASCULARIZATION; STENT THROMBOSIS; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; WESTERN HEMISPHERE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS; DRUG-ELUTING STENTS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; REGISTRIES; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 77953712398     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.184150     Document Type: Article

References (18)

1. Hermiller JB, Raizner A, Cannon L, et al. TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1206-12.
2. Kirtane AJ, Ellis SG, Dawkins KD, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus. J Am Coll Cardiol 2008;51:708-15.
3. Fajadet J, Wijns W, Laarman G-J, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for the treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
4. Kandzari DE, Leon MB, Popma JJ, et al. for the ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7.
5. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55:543-54.
6. Jain AK, Meredith IT, Lotan C, et al. Real-world safety and efficacy of the Endeavor zotarolimus-eluting stent: early data from the E-Five registry. Am J Cardiol 2007;100(8B):77M-83M.
7. Lotan C, Meredith IT, Mauri L, et al. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five Registry. JACC Cardiovasc Interv 2009;2;1227-35.
8. Cutlip DE, Windecker S, Mehran R, et al. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
9. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting Endeavor stent. J Interv Cardiol 2006;19:405-13.
10. Kumar R, Lee TT, Jeremias A, et al. Comparison of outcomes using sirolimuseluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol 2007;100:1187-91.
11. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-41.
12. Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel and sirolimus-eluting stents: Results from a large prospective multicenter registry - STENT group. J Am Coll Cardiol 2007;50:1214-22.
13. Waksman R, Buch AN, Torguson R, et al. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry). Am J Cardiol 2007;100:45-51.
14. Seabra-Gomes R. Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart 2006;92:410-19. (Pubitemid 43295124)
15. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
16. Ong AT, Aoki J, van Mieghem CA, et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005;96:358-62.
17. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
18. Iijima R, Ndrepepa G, Mehilli J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007;154:688-93.